NEW YORK (GenomeWeb News) – Premier Biosoft said on Monday it has completed the acquisition of NuSep's software business ProteoIQ for an undisclosed amount.
The acquisition launches Palo Alto, Calif.-based Premier into the proteomics market. Premier already operates in the lipidomics, glycomics, and MALDI imaging analysis spaces. In October, it announced an agreement with Agilent Technologies to support the combination of each other's technologies to advance lipidomics research, and in June the company said it had reached a co-marketing and reselling deal with Danaher's AB Sciex for lipidomic research software.
ProteoIQ is software for proteomics analysis that streamlines statistical validation, protein quantification, and comparative proteomics onto one platform, Premier said. The software supports validation of proteins identified by other database search tools such as Mascot, Sequest, or X!Tandem, and can be used for quantitative analysis performed by spectral counting, precursor intensity, iTRACQ, TMT, SILAC, and iCAT workflows.
"For the rapidly growing proteomics market, ProteoIQ is a strategic fit to Premier Biosoft's existing mass spec product offering and helps consolidate our position as a leader for providing informatics tools for mass spectrometry," Premier's CEO Arun Apte said in a statement.
NuSep, a Sydney-based life science firm, announced Premier had made an offer for ProteoIQ earlier this year. It deemed the software business a non-core operation and said that the divestiture would free up the firm to concentrate on its core businesses in the bioseparations market.